News & Videos - ANTARES PHARMA INC. - English

Halozyme Completes Antares Pharma Acquisition PR Newswire SAN DIEGO, May 24, 2022 SAN DIEGO , May 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced the successful completion of its acquisition of Antares Pharma, Inc. (" Antares "). The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time , on Monday, May 23, 2022 . The minimum tender condition and all of the other...

Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO, May 12, 2022 SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the " HSR Act "), applicable to Halozyme's proposed acquisition of Antares Pharma, Inc. (NASDAQ: ATRS) (" Antares ") has expired. On April 26, 2022 , Halozyme...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the proposed transaction, shareholders of Antares will receive only $5.60 in cash for each share of Antares that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether...

Kuznicki Law PLLC is investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the proposed transaction, shareholders of Antares will receive only $5.60 in cash for each share of Antares that they own. If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email ( [email protected] ), or visit...

HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA PR Newswire SAN DIEGO, April 26, 2022 SAN DIEGO , April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. (" Purchaser "), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ: ATRS) (" Antares ") for $5.60 per share in cash. The...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the proposed transaction, shareholders of Antares will receive only $5.60 in cash for each share of Antares that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether...

SHAREHOLDER ALERT: Weiss Law Investigates Antares Pharma, Inc. PR Newswire NEW YORK, April 13, 2022 NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS), in connection with the proposed acquisition of the Company by Halozyme Therapeutics, Inc. (NASDAQ: HALO) via a tender offer. Under the terms of the merger agreement, the...

Thinking about buying stock in Antares Pharma, Celsion Corp, American Airlines, Kaleido Biosciences, or CTI BioPharma? PR Newswire NEW YORK, April 13, 2022 NEW YORK , April 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATRS, CLSN, AAL, KLDO, and CTIC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ATRS:...

Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Antares Pharma, Inc. (NASDAQ: ATRS) to Halozyme Therapeutics, Inc. for $5.60 per share in cash is fair to Antares Pharma shareholders. Halper Sadeh encourages Antares Pharma shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected] . The investigation concerns whether Antares Pharma...

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader PR Newswire SAN DIEGO and EWING, N.J., April 13, 2022 Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Growing Testosterone Replacement Therapy...

Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO® PR Newswire SALT LAKE CITY, Oct. 18, 2021 SALT LAKE CITY , Oct. 18, 2021 /PRNewswire/ -- Under the terms of Agreement Lipocine to receive: Up to $21.0 million in licensing fees, including $11.0 million payable immediately and $10.0 million to be paid in the future subject to certain conditions Commercial sales milestone payments of up to $160.0 million Tiered royalties on net sales of TLANDO from mid-teens...

...

...

...

...

...

...

...

...

...